KLOW Stack (BPC-157 + TB-500 + GHK-Cu + KPV)
A research overview of the KLOW Stack, the Glow Stack (BPC-157 + TB-500 + GHK-Cu) with the addition of KPV, an anti-inflammatory tripeptide derived from alpha-MSH. KPV adds targeted NF-κB inhibition and mucosal anti-inflammatory activity to the tissue repair and remodeling profile of the Glow Stack. Four mechanistically distinct compounds targeting complementary aspects of tissue repair and inflammation.
Science simplified
The KLOW Stack is the most comprehensive recovery and anti-inflammatory protocol on PSI, combining BPC-157, TB-500, GHK-Cu, and KPV. KPV is a tiny anti-inflammatory peptide that enters cells directly and blocks a key inflammatory pathway. Adding it to the Glow Stack creates a four-compound protocol targeting tissue repair, systemic recovery, skin remodeling, and cellular inflammation simultaneously. No human trials exist for any combination of these compounds.
Best researched for
Recovery · inflammation · remodeling · skin repair
Evidence stage
Individual compound data · no combination trials
Approval status
No compounds FDA-approved · research use only
Animal Studies through Human Trials/Animal Studies through Human Trials/Animal Studies
Compound Evidence Levels
None
Combination Trial Data
4
Compounds
Multi-Mechanism
Anti-inflammatory Approach
PSI Verdict
Supported by evidence
The KLOW Stack combines compounds targeting cellular repair, inflammation reduction, and metabolic optimization through distinct mechanisms. The individual compounds address complementary aspects of recovery and longevity with independent preclinical support. The mechanistic logic of addressing multiple recovery pathways simultaneously reflects genuine scientific reasoning about systemic repair.
Not yet established
Combination evidence does not exist for this stack. The specific compound interactions, pharmacokinetic compatibility, and combined safety profile have not been studied. The breadth of claimed benefits across multiple systems increases rather than decreases the evidence burden that has not been met.
Confidence level
The KLOW Stack's multi-system approach is mechanistically ambitious. The individual compound evidence supports the rationale for each mechanism addressed. The combination has not been studied and the breadth of the protocol means the evidence gap is proportionally larger than more focused stacks.
Stack Rationale
Extension of the Glow Stack: The KLOW Stack builds on the Glow Stack (BPC-157 + TB-500 + GHK-Cu) by adding KPV as a fourth compound targeting direct NF-κB inhibition and mucosal anti-inflammatory activity.
BPC-157: Drives angiogenesis and structural repair via VEGF and GH receptor pathways across multiple tissue types.
TB-500: Drives cell migration via actin upregulation and cytokine suppression (TNF-α, IL-6) at the extracellular signaling level.
GHK-Cu: Modulates over 4,000 genes, promotes collagen and elastin synthesis, and drives tissue remodeling via TGF-β and VEGF upregulation.
KPV: Adds a fourth mechanism, direct NF-κB inhibition via PepT1 transporter, reducing TNF-α, IL-1β, and IL-6 at the intracellular level. Derived from alpha-MSH, KPV retains anti-inflammatory properties without the melanogenic or cardiovascular effects of the parent molecule. The combined anti-inflammatory profile of TB-500 (cytokine suppression) and KPV (NF-κB inhibition) represents complementary rather than redundant activity targeting different points in the inflammatory cascade.
Important limitation: No combination trials exist for this four-compound protocol. The stack rationale is derived entirely from individual compound profiles. Interaction effects, safety of combined use, and additive or synergistic outcomes are unknown.
In everyday terms: KPV is the fourth compound in the KLOW Stack, a tiny three-amino-acid peptide that gets inside cells and turns off a master inflammation switch called NF-κB. Think of the Wolverine Stack as the repair crew, GHK-Cu as the remodeling crew, and KPV as the crew that turns off the alarm system so the others can work without interference.
Compound Profiles
A gastric pentadecapeptide that promotes angiogenesis and growth factor signaling across multiple tissue types. Strong and consistent animal data for tendon, ligament, muscle, bone, and gut repair. Limited human clinical data. Classified as Human Trials (Moderate Evidence).
A synthetic fragment of thymosin beta-4 that promotes actin-mediated cell migration and anti-inflammatory signaling via TNF-α and IL-6 suppression. Early-phase human trial data exists for wound healing via the parent molecule. Classified as Animal Studies (Preliminary Evidence).
A naturally occurring tripeptide-copper complex that modulates over 4,000 human genes, promotes collagen and elastin synthesis, and resets gene expression patterns toward healthier phenotypes. Extensive cosmetic safety data. Animal Studies through Human Trials contextual.
A C-terminal tripeptide fragment of alpha-MSH that inhibits NF-κB nuclear translocation, reducing TNF-α, IL-1β, and IL-6 at the intracellular level. Enters cells via PepT1 transporter. Studied for inflammatory bowel disease and skin inflammation. Retains anti-inflammatory properties without melanogenic or cardiovascular effects. Classified as Animal Studies (Preliminary Evidence).
Mechanistic Comparison
| Dimension | BPC-157 | TB-500 | GHK-Cu | KPV |
|---|---|---|---|---|
| Primary mechanism | Angiogenesis + GH receptor | Actin + cell migration | Gene expression + collagen | NF-κB inhibition |
| Anti-inflammatory target | Growth factor signaling | TNF-α, IL-6 suppression | MMP modulation | NF-κB, TNF-α, IL-1β, IL-6 |
| Tissue focus | Tendon, gut, bone | Muscle, cardiac, dermal | Skin, connective tissue | Gut mucosa, skin |
| Evidence level | Human Trials | Animal Studies | Animal Studies through Human Trials | Animal Studies |
Evidence Summary
What people commonly research this for
- , Comprehensive recovery with active anti-inflammatory support
- , Gut inflammation and gut lining repair research
- , Full spectrum tissue repair and remodeling protocols
Most comprehensive recovery stack on PSI. Individual compound evidence is moderate to preliminary. No combination trials exist. Not FDA-approved.
Individual Compound Evidence
BPC-157 is rated Human Trials (Moderate Evidence) with strong animal data across multiple tissue types. TB-500 is rated Animal Studies (Preliminary Evidence) with early-phase human trial data via thymosin beta-4. GHK-Cu is rated Animal Studies through Human Trials contextual with extensive cosmetic use data and gene expression research. KPV is rated Animal Studies (Preliminary Evidence) with preclinical data in inflammatory bowel disease and skin inflammation models.
Combination Evidence
No controlled studies have evaluated this four-compound protocol. Each compound has been studied individually; no data exists for any pairwise or multi-compound combination from this stack. Whether these compounds interact, produce additive effects, or carry additional safety considerations when combined is not established in published research.
Safety Considerations
Individual Safety Profiles
BPC-157 has a favorable safety profile in animal studies with limited human safety data. TB-500 has generally favorable early-phase human trial data via thymosin beta-4. GHK-Cu has an excellent safety profile from decades of cosmetic and dermatological use. KPV is derived from an endogenous peptide (alpha-MSH) with preclinical studies showing favorable safety without melanogenic or cardiovascular effects of the parent molecule.
Combination Safety. Unknown
No safety data exists for this four-compound protocol. Drug interaction potential, combined tissue effects, cumulative anti-inflammatory activity, and dosing considerations have not been studied. The absence of combination data means safety cannot be assumed. Caution is warranted for any untested multi-compound protocol.
Research Context
Researchers interested in the individual mechanisms behind this stack can review the full compound profiles for BPC-157, TB-500, GHK-Cu, and KPV.
The two-compound foundation of this protocol is covered on the Wolverine Stack (BPC-157 + TB-500) page.
The three-compound variant is covered on the Glow Stack (BPC-157 + TB-500 + GHK-Cu) page.
For a broader overview of peptides studied for musculoskeletal growth and repair, see the peptides for muscle growth roundup.
This stack is reviewed in the context of the broader injury recovery research literature on this site.
For peptides studied for immune modulation and anti-inflammatory activity, see the peptides for immune support roundup.
Medical Disclaimer
This page is for informational and educational purposes only and does not constitute medical advice. KPV, LL-37, Oxytocin, and Thymosin Alpha-1 are research compounds not approved for human therapeutic use as a stack. Always consult a qualified healthcare professional. PSI aggregates publicly available research and does not conduct original clinical trials.